Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review

In managing prostate cancer, the integration of multidisciplinary team (MDT) with prostate-specific membrane antigen (PSMA) theranostics marks a significant advancement, addressing the disease's spectrum from indolent forms to aggressive metastatic stages. MDTs, comprising urology, oncology, ra...

Full description

Saved in:
Bibliographic Details
Main Authors: Minseok Suh, Gi Jeong Cheon
Format: Article
Language:English
Published: Korean Urological Oncology Society 2024-03-01
Series:Journal of Urologic Oncology
Subjects:
Online Access:http://www.e-juo.org/upload/pdf/juo-244600200010.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846143063810899968
author Minseok Suh
Gi Jeong Cheon
author_facet Minseok Suh
Gi Jeong Cheon
author_sort Minseok Suh
collection DOAJ
description In managing prostate cancer, the integration of multidisciplinary team (MDT) with prostate-specific membrane antigen (PSMA) theranostics marks a significant advancement, addressing the disease's spectrum from indolent forms to aggressive metastatic stages. MDTs, comprising urology, oncology, radiation oncology, pathology, radiology, and nuclear medicine experts, are pivotal in delivering tailored, evidence-based care, essential for the varied clinical presentations of prostate cancer. The introduction of PSMA-targeted theranostics and PSMA positron emission tomography imaging has impacted the approach to diagnosis and treatment, offering enhanced precision in disease localization and enabling more nuanced management strategies for conditions such as oligometastatic prostate cancer, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. The collaborative approach of MDTs in utilizing PSMA-targeted radioligand therapy emphasizes meticulous patient selection, predictive assessment of therapy response, and careful management of therapy-related toxicities. Additionally, recent strategies, including combination therapies from ENZA-P and Lu-PARP trials, show potential for improving treatment efficacy. This unified approach showcases the critical role of MDTs in optimizing treatment outcomes, underscoring the importance of collaboration in advancing the treatment of prostate cancer with PSMAtargeted therapies, thereby setting a new paradigm in personalized prostate cancer management.
format Article
id doaj-art-421c02edd92646f5bdf5e7715ddf7292
institution Kabale University
issn 2951-603X
2982-7043
language English
publishDate 2024-03-01
publisher Korean Urological Oncology Society
record_format Article
series Journal of Urologic Oncology
spelling doaj-art-421c02edd92646f5bdf5e7715ddf72922024-12-03T04:18:38ZengKorean Urological Oncology SocietyJournal of Urologic Oncology2951-603X2982-70432024-03-01221112010.22465/juo.244600200010568Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative ReviewMinseok Suh0Gi Jeong Cheon1 Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KoreaIn managing prostate cancer, the integration of multidisciplinary team (MDT) with prostate-specific membrane antigen (PSMA) theranostics marks a significant advancement, addressing the disease's spectrum from indolent forms to aggressive metastatic stages. MDTs, comprising urology, oncology, radiation oncology, pathology, radiology, and nuclear medicine experts, are pivotal in delivering tailored, evidence-based care, essential for the varied clinical presentations of prostate cancer. The introduction of PSMA-targeted theranostics and PSMA positron emission tomography imaging has impacted the approach to diagnosis and treatment, offering enhanced precision in disease localization and enabling more nuanced management strategies for conditions such as oligometastatic prostate cancer, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. The collaborative approach of MDTs in utilizing PSMA-targeted radioligand therapy emphasizes meticulous patient selection, predictive assessment of therapy response, and careful management of therapy-related toxicities. Additionally, recent strategies, including combination therapies from ENZA-P and Lu-PARP trials, show potential for improving treatment efficacy. This unified approach showcases the critical role of MDTs in optimizing treatment outcomes, underscoring the importance of collaboration in advancing the treatment of prostate cancer with PSMAtargeted therapies, thereby setting a new paradigm in personalized prostate cancer management.http://www.e-juo.org/upload/pdf/juo-244600200010.pdfprostatic neoplasmsprostate-specific membrane antigenmultidisciplinary teamtheranostics
spellingShingle Minseok Suh
Gi Jeong Cheon
Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
Journal of Urologic Oncology
prostatic neoplasms
prostate-specific membrane antigen
multidisciplinary team
theranostics
title Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
title_full Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
title_fullStr Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
title_full_unstemmed Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
title_short Multidisciplinary Team Approach in Prostate-Specific Membrane Antigen Theranostics for Prostate Cancer: A Narrative Review
title_sort multidisciplinary team approach in prostate specific membrane antigen theranostics for prostate cancer a narrative review
topic prostatic neoplasms
prostate-specific membrane antigen
multidisciplinary team
theranostics
url http://www.e-juo.org/upload/pdf/juo-244600200010.pdf
work_keys_str_mv AT minseoksuh multidisciplinaryteamapproachinprostatespecificmembraneantigentheranosticsforprostatecanceranarrativereview
AT gijeongcheon multidisciplinaryteamapproachinprostatespecificmembraneantigentheranosticsforprostatecanceranarrativereview